117708-90-4

Upstream product

• 117666-29-2 (+/-)-3,6-di-O-allyl-4-O-benzyl-1,2-O-cyclohexylidene-myo-inositol 
• 112204-05-4 (+/-)-3,6-di-O-allyl-1,2-O-cyclohexylidene-myo-inositol 
• 211799-65-4 (+)-3-O-allyl-4-O-benzyl-1,2:5,6-di-O-cyclohexylidene-myo-inositol 
• 211799-66-5 (-)-3-O-allyl-4-O-benzyl-1,2-O-cyclohexylidene-myo-inositol 
• 116907-54-1 6-O-benzyl-2,3:4,5-di-O-cyclohexylidene-1-L-myo-inositol 
• 33021-17-9 (-)-2,3:4,5-di-O-cyclohexylidene-myo-inositol 
• 211799-67-6 (-)-3,5,6-tri-O-allyl-4-O-benzyl-1,2-O-cyclohexylidene-myo-inositol 
• 136986-26-0 rac-1,3,4-Tri-O-allyl-5,6-O-isopropylidene-myo-inositol 
• 98906-37-7 (3aR,4S,5S,6S,7S,7aR)-4,5,7-Tris-allyloxy-6-benzyloxy-2,2-dimethyl-hexahydro-benzo[1,3]dioxole 
• 6404-82-6 (+/-)-1,2-O-isopropylidene-myo-inositol 
• 87-89-8 D-myo-inositol 
• 98906-34-4 (±)-2,3-O-isopropylidene-1,4-di-O-allyl-6-O-benzyl-myo-inositol 
• 98906-33-3 (±)-1,4-di-O-allyl-2,3-O-isopropylidene-myo-inositol 
• 98906-32-2 (±)-1,4-di-O-allyl-2,3:5,6-di-O-isopropylidene-myo-inositol 

Downstream Products

• 98925-54-3 (±)-2,3,6-tri-O-benzyl-1,4,5-tri-O-allyl-myo-inositol 
• 211869-76-0 (+)-3,5,6-tri-O-allyl-2,4-di-O-benzyl-1-O-(p-methoxybenzyl)-myo-inositol 
• 187980-90-1 Phosphoric acid dibenzyl ester (1S,2R,3S,4S,5R,6S)-2,6-bis-benzyloxy-3,4-bis-(bis-benzyloxy-phosphoryloxy)-5-(4-methoxy-benzyloxy)-cyclohexyl ester 
• 187980-91-2 Phosphoric acid dibenzyl ester (1S,2S,3R,4S,5S,6R)-3,5-bis-benzyloxy-2,4-bis-(bis-benzyloxy-phosphoryloxy)-6-hydroxy-cyclohexyl ester 
• 145789-74-8 1D-2,4-di-O-benzyl-1-O-p-methoxybenzyl-myo-inositol 
• 211799-68-7 (1R,2S,3R,4R,5S,6R)-2,4,5-Tris-allyloxy-3-benzyloxy-6-(4-methoxy-benzyloxy)-cyclohexanol 
• 98925-54-3 (+)-1,3,4-tri-O-allyl-2,5,6-tri-O-benzyl-myo-inositol 
• 141040-46-2 (1R,2R,3S,4R,5S,6S)-3,4,6-Tris-allyloxy-5-benzyloxy-cyclohexane-1,2-diol 
• 141040-49-5 (1S,2S,3R,4S,5R,6R)-3,4,6-Tris-allyloxy-5-benzyloxy-cyclohexane-1,2-diol 
• 140886-99-3 Phosphorous acid dibenzyl ester (1R,2S,3S,4R,5R,6R)-2,3,6-tris-benzyloxy-4,5-bis-(bis-benzyloxy-phosphanyloxy)-cyclohexyl ester 
• 140887-03-2 Phosphoric acid benzyl ester (1R,2S,3S,4R,5R,6R)-2,3,6-tris-benzyloxy-4,5-bis-(benzyloxy-hydroxy-phosphoryloxy)-cyclohexyl ester 
• 141116-53-2 C₄₈H₄₈O₁₅P₃^(3-)*3Na⁽¹⁺⁾ 
• 114419-08-8 (+)-1L-2,5,6-tri-O-benzyl-myo-inositol 
• 114419-09-9 (-)-1L-2,5,6-tri-O-benzyl-1,3,4-tris(dibenzylphospho)-myo-inositol 

Relevant academic research and scientific papers

Synthesis and in vitro anticancer activity evaluation of novel bioreversible phosphate inositol derivatives

The chemistry and biology of phosphorylated inositols have become intense areas of research during the last two decades due to their involvement in various cellular signaling processes. However, the metabolic instability by phosphatases or kinases and poo

Molecular Recognition at the Phosphatidylinositol 3,4,5-Trisphosphate-Binding Site. Studies Using the Permuted Isomers of Phosphatidylinositol Trisphosphate

Permuted isomers of L-α-phosphatidyl-D-myo-inositol trisphosphate (PtdInsP3), including PtdIns(3,4,5)P3, PtdIns(3,4,6)P3, PtdIns(3,5,6)P3, and PtdIns(4,5,6)P3, have been synthesized as part of our effort to understand the underlying principles governing ligand selection for PtdIns(3,4,5)P3-specific binding proteins. These PtdInsP3 isomers are examined by using two PtdIns(3,4,5)P3-dependent functional assays: binding to the C-terminal SH2 domain of the p85 regulatory subunit of PI 3-kinase and platelet aggregation. Our data show that all these isomers bind to the SH2 domain with comparable affinity despite variation in the regioisomeric distribution of phosphate functions. Moreover, all these phospholipids are capable of triggering platelet aggregation with the relative potency of PtdIns(3,4,5)P3 > PtdIns(3,5,6)P3 > PtdIns(4,5,6)P3 > PtdIns(3,4,6)P3. Evidence suggests that these PtdInsP3's facilitate cell aggregation by activating Ca2+ influx across the plasma membrane. In contrast, other inositol lipids examined including PtdIns(3,4)P2, PtdIns(4,5)P2, PtdIns(3)P, and PtdIns(4)P are ineffective in eliciting the aggregation even at much higher concentrations. Taken together, the present data suggest that the charge density on the phosphorylated inositol ring represents a key factor in determining the phosphoinositide binding specificity of target proteins. It is conceivable that the interaction with the PtdIns(3,4,5)P3-binding motif requires the participation of all three phosphates on the headgroup of PtdIns(3,4,5)P3. Consequently, other membrane phosphoinositides (e.g., the bis- and monophosphates) become thermodynamically unfavorable for the binding to these PtdIns(3,4,5)P3 targets.

The preparation, resolution, and phosphorylation of some benzyl ethers of myo-inositol: Intermediates for the synthesis of myo-inositol phosphates of the phosphatidylinositol cycle

The syntheses of the following chiral compounds are described: 1D-2,3,6-tri-, 1D-2,4,5-tri, 1D-2,5,6-tri-, 1D-1,2,3,4-tetra, 1D-1,2,3,6-tetra-, 1D-1,2,4,5-tetra-, and 1D-2,3,5,6-tetra-0-benzyl-myo-inositol; and 1D-2,5,6-tri-0-benzyl-1-0-p-methoxybenyl- an

TOTAL SYNTHESIS OF OPTICALLY ACTIVE MYO-INOSITOL 1,4,5-TRISPHOSPHATE AND MYO-INOSITOL 1,3,4,5-TETRAKISPHOSPHATE

A convenient approach to the preparation of the title compounds illustrating selective protection, optical resolution and phosphorylation is presented.

The Allyl Group for Protection in Carbohydrate Chemistry. Part 18. Allyl and Benzyl Ethers of myo-Inositol. Intermediates for the Synthesis of myo-Inositol Triphosphates

Racemic 1,2:4,5-di-O-isopropylidene-myo-inositol was converted into racemic 1,2,4-tri-O-benzyl-myo-inositol, 1,2,4-tri-O-p-methoxybenzyl-myo-inositol and 2,4,5-tri-O-benzyl-myo-inositol using allyl groups for 'temporary' protection.The benzyl ethers are required as intermediates for the synthesis of the 'second messenger', inositol 1,4,5-triphosphate and its metabolite, inositol 1,3,4-triphosphate. 1,2,3,4-Tetra-O-benzyl-myo-inositol, and its two monoallyl and monoprop-1-enyl ethers, were also prepared as model compounds for phosphorylation studies of the vicinal 5,6-diol system which occurs in 1,2,4-tri-O-benzyl-myo-inositol.